Don Lenc

Regional Urogenomic Liaison with Genomic Health

[ArteraAI @arteraAI]

Every pathology slide tells a story.

Artera's multimodal AI assesses comprehensive tumor biology from routine H&E slides to support more personalized treatment decisions.

https://t.co/omY5V4f9Jh

#DigitalPathology #PrecisionMedicine

[ArteraAI @arteraAI]

How are clinicians using AI in #prostatecancer care?

Watch Dr. Elisabeth Heath discuss the role of AI-based biomarkers, multidisciplinary care, and shared decision-making in this @UroToday interview: https://t.co/wxetRV58fp

#AIinHealthcare #ArteraAI

[ArteraAI @arteraAI]

Dr. Ben Fischer-Valuck will be representing Artera at #USPCCC2026.

Looking forward to another great meeting and conversations advancing the future of #ProstateCancer care.

#PrecisionMedicine #ArteraOnTheGo

[ArteraAI @arteraAI]

The ArteraAI Prostate Test (#mHSPC) provides individualized risk estimates, including risk percentile and 5-year PCSM risk on ADT + ARPI.

Higher-than-expected risk may help inform treatment intensification.

Learn more: https://t.co/EdXJuMY2ej

[Zeyad Schwen MD @ZSchwen]

GG1 Prostate Cancer can (rarely) be locally advanced!

➡️ BCR rate is low (10% at 15 yrs) and slow (only 3.2% at 5 years) and not resulting in mets or death

Congrats @MWatfa26 💪 💪
@JaneNguyen44 @GaganFervaha @CleClinicUro

[ArteraAI @arteraAI]

Risk stratification after prostatectomy remains a key challenge in #prostatecancer care.

Watch Dr. R. Jeffrey Karnes discuss the external validation of a multimodal AI prognostic model in this @UrologyTimes Special Report: https://t.co/Y1bd1rVrGm

#AIinHealthcare #ArteraAI

[ArteraAI @arteraAI]

Rethinking what's possible in #BreastCancer care.

Learn how The #ArteraAI Breast Cancer Test delivers personalized prognostic insights through multimodal AI.

Explore the benefits: https://t.co/lP158EiQrO

#AIinHealthcare #DigitalPathology

[ArteraAI @arteraAI]

Not all high-risk #prostatecancer patients benefit equally from treatment intensification.

See how the #ArteraAI Prostate Test may help personalize care decisions, especially around the use of abiraterone.

Read more: https://t.co/ppE6DSfrhs

[Dr. Ronney Abaza @DrRonneyAbaza]

Check out my new video on YouTube. This should be most helpful for residents and fellows as they start looking for their first job!

How to Choose a Urology Job that Fits You by Dr. Ronney Abaza https://t.co/1qpkuWVGme via @YouTube

[AI_4_Healthcare @AI_4_Healthcare]

🧠 𝑩𝒓𝒂𝒊𝒏 𝑻𝒖𝒎𝒐𝒖𝒓 𝑫𝒊𝒂𝒈𝒏𝒐𝒔𝒊𝒔: 𝑭𝒓𝒐𝒎 𝑾𝒆𝒆𝒌𝒔 𝒕𝒐 𝑴𝒊𝒏𝒖𝒕𝒆𝒔

Many of my #AIinHealthcare posts are about future potential; this one is about current performance.

Hetairos, developed by researchers at @DKFZ German Cancer Research Center and the University of Heidelberg, predicts 102 molecular subtypes of CNS tumours directly from standard H&E-stained tissue slides.

These are glass microscope slides holding micro-thin slices of biological tissue that have been treated with two specific dyes: hematoxylin and eosin (yeah, I asked AI to explain this 😉), which is considered the global gold standard in 80% of medical tissue diagnostics.

This can change pathology, now! Instead of 12 days for a molecular workup, answers in as little as 12 minutes.

This is a 99.93% time compression.
It is effectively workflow obliteration!
Boom ... 💣

The model was trained and validated on over 11,000 slides from 9,606 patients across 11 facilities and four continents ... the data is robust and generalizable.

In high-confidence cases, accuracy reached 87%. And in a blinded comparison, it outperformed five board-certified neuropathologists on histology-only classification (68% vs 30%). It was tested in real diagnostic workflows, not just benchmarked in controlled conditions.

Here's why this really matters: DNA methylation profiling, as noted above is the gold standard, but it is expensive, time-consuming, and simply unavailable across most of the world.

On the other hand, Hetairos runs on hardware most pathology labs already have. This is a big #HealthEquity win.

Importantly, the five neuropathologists HetAIros outperformed were working without clinical context. The tool used age and tumour location alongside the slide. It wasn't a fair fight.

And to be clear, this is not a call to "replace pathologists". Hetairos narrows differentials and flags tissue regions of interest. It's a force multiplier for expert judgment, not a substitute and elevates the critical skills and judgment of a pathologist.

This is an example of AI as "infrastructure" done right in diagnostic medicine; prospective validation, real-world deployment, honest confidence scoring, and equity-conscious design.

This is #ResponsibleAI in healthcare.

Nature: https://t.co/K27wKG2tdD

DKFZ: https://t.co/gczphtN5JP

@LundinCancer @cancersociety

[Laura Bukavina @LauraBukavinaMD]

Honored to receive support from @ClevelandClinic and @bikeVeloSano for our bladder cancer biomarker study. Using MRI, 🩸urine/plasma ctDNA and AI, we aim to better predict cCR/pCR and identify the RIGHT candidates for bladder preservation. Grateful to work with @AmandaNizamMD and @Purysko .. I also see our fabulous @MoningiShalini and her study 📚 >>> https://t.co/iEy2dlOGPU

[Daniel E Spratt @DrSpratticus]

🚨 Recruitment Alert 🚨

We are looking to recruit 2 outstanding new graduates who will soon be entering PGY-5 (graduate 2027)!

Interested candidates are encouraged to apply! Expanding at our main campus and 2 academic network hubs.

Join one of the fastest growing teams in the country with expansive technology, wonderful people, amazing culture.

Email Kim Vargo if interested! [email protected]

@ASTRO_org @ASTRO_Chair @NehaVapiwala @ARRO_org @ACROresident @ACRORadOnc @lauren_henke @angela_jia_ @UHhospitals @UH_RE_Institute @TedTeknosMD @SimonLo21054188 @DanSimonMD @AmarUKishan @alison_tree @neerajaiims @ASCO @DrChoueiri @DrewMoghanaki @DrAndrewLoblaw @UroCancer @uroegg @freddyeescorcia @EricTopol @shilpaonc @wandering_gu @HimanshuNagarMD @SbrtSean @jmmrad @subatomicdoc @seanmmcbride @NicholasZaorsky @piet_ost @TylerSbrt @QuadShotNews @urotoday @sueyom @KashaniRojano @PranshuMohindra @RaedZuhour

[Jayram Krishnan DO MBA @AskDoctorJay]

#BladderCancerAwarenessMonth https://t.co/agDujaminT

[Brad Gill @BradGillMD]

Great work by @CleClinicUro research fellow @MWatfa26 highlighted across multiple #AUA2026 abstracts!

Heads up residency programs! He is coming your way soon.

[Zeyad Schwen MD @ZSchwen]

Congrats Mohamad on a successful #AUA26 !!

Keep pushing 💪

[Nicolas Soputro @NicolasSoputro]

Thank you for featuring our work from #SPARC. Check out our recently published manuscript as well at @EurUrolOncol https://t.co/d6IVPTkVqq @drjkaouk @ricautor @CleClinicUro

[Laura Bukavina @LauraBukavinaMD]

It was a privilege to lead this course alongside such an outstanding faculty @AdamCalaway @abhitrip87 @samhaywoodmd @MoningiShalini Thank you all for helping make this such a meaningful and impactful discussion on advancing care for patients with MIBC @CleClinicUro #aua26

[Laura Bukavina @LauraBukavinaMD]

Don’t miss the @IBCG_BladderCA session happening now an incredible slate of experts diving into the most pressing clinical questions in #bladdercancer. Follow Flo to Salon H! 🟡 @MoningiShalini @shilpaonc #aua26

[Nicolas Soputro @NicolasSoputro]

Packed room at our annual #SPARC event celebrating the successful #SP collaboration and productive #AUA26 with 17 abstracts presented from the group @CleClinicUro @drjkaouk

[Nicolas Soputro @NicolasSoputro]

Thank you #AUA26 for the best poster award for our work evaluating preoperative predictors of immediate urinary continence following #SP Transvesical Robotic Radical Prostatectomy @CleClinicUro @drjkaouk